within Pharmacolibrary.Drugs.ATC.L;

model L01EX19
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.77,
    Cl             = 0.00019499999999999997,
    adminDuration  = 600,
    adminMass      = 150 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.238,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005833333333333333,
    Tlag           = 9.96,            
    Vdp             = 0.126,
    k12             = 23.6,
    k21             = 23.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EX19</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ripretinib is a tyrosine kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. It is approved for clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for oral ripretinib 150 mg once daily in adult patients with advanced GIST. Data are primarily from healthy volunteers and patients with GIST, both male and female, middle-aged.</p><h4>References</h4><ol><li><p>Mudavath, S, &amp; Ashok, D (2023). Effect of Verapamil, a P-glycoprotein-1 and Cytochrome P450 3A4 Inhibitor, on Pharmacokinetics and Metabolic Stability of Ripretinib: A Drug-Drug Interaction Study in Rats. <i>European journal of drug metabolism and pharmacokinetics</i> 48(6) 733–746. DOI:<a href=&quot;https://doi.org/10.1007/s13318-023-00860-6&quot;>10.1007/s13318-023-00860-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37831396/&quot;>https://pubmed.ncbi.nlm.nih.gov/37831396</a></p></li><li><p>Pan, C, et al., &amp; Xiang, X (2023). Evaluating the impact of co-administered drug and disease on ripretinib exposure: A physiologically-based pharmacokinetic modeling approach. <i>Chemico-biological interactions</i> 373 110400–None. DOI:<a href=&quot;https://doi.org/10.1016/j.cbi.2023.110400&quot;>10.1016/j.cbi.2023.110400</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36773833/&quot;>https://pubmed.ncbi.nlm.nih.gov/36773833</a></p></li><li><p>Wang, HJ, et al., &amp; Qiu, XJ (2021). The Pharmacokinetic Effect of Itraconazole and Voriconazole on Ripretinib in Beagle Dogs by UPLC-MS/MS Technique. <i>Drug design, development and therapy</i> 15 4865–4873. DOI:<a href=&quot;https://doi.org/10.2147/DDDT.S337864&quot;>10.2147/DDDT.S337864</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34876808/&quot;>https://pubmed.ncbi.nlm.nih.gov/34876808</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EX19;
